127 related articles for article (PubMed ID: 10965743)
1. [PSA doubling time in prostate cancer relapsed after endocrine therapy].
Nakata S; Takahashi H; Takezawa Y; Kobayashi M; Matumoto K; Kosaku N; Kawashima K
Nihon Hinyokika Gakkai Zasshi; 2000; 91(7-8):584-8. PubMed ID: 10965743
[TBL] [Abstract][Full Text] [Related]
2. [PSA-related parameters in prostate cancer relapsed after endocrine therapy].
Nakata S; Takahashi H; Takezawa Y; Kobayashi M; Matumoto K; Kosaku N; Kawashima K
Nihon Hinyokika Gakkai Zasshi; 2002 Sep; 93(6):686-93. PubMed ID: 12385093
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors for PSA relapse of prostate cancer after endocrine therapy].
Nakata S; Nakano K; Takahashi H; Shimizu K; Kawashima K
Nihon Hinyokika Gakkai Zasshi; 2005 Nov; 96(7):685-90. PubMed ID: 16363654
[TBL] [Abstract][Full Text] [Related]
4. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
Pollack A; Zagars GK; el-Naggar AK; Terry NH
Urology; 1994 Nov; 44(5):711-8. PubMed ID: 7526527
[TBL] [Abstract][Full Text] [Related]
5. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients.
Oudard S; Banu E; Scotte F; Banu A; Medioni J; Beuzeboc P; Joly F; Ferrero JM; Goldwasser F; Andrieu JM
Ann Oncol; 2007 Nov; 18(11):1828-33. PubMed ID: 17846024
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen in patients with relapsed prostate cancer following endocrine treatment.
Kubota Y; Yanai H; Sasagawa I; Suzuki H; Nakada T; Sugano O
Int Urol Nephrol; 1996; 28(3):349-55. PubMed ID: 8899475
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
Pollack A; Zagars GK; Kavadi VS
Cancer; 1994 Jul; 74(2):670-8. PubMed ID: 7518341
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study on poor PSA response to initial endocrine therapy with MAB or estrogenic drugs for treatment of prostate cancer].
Nakata S; Furuya Y; Hasumi M; Nakano K; Takahashi H
Nihon Hinyokika Gakkai Zasshi; 2007 Nov; 98(7):803-7. PubMed ID: 18062210
[TBL] [Abstract][Full Text] [Related]
10. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
D'Amico AV; Moul JW; Carroll PR; Sun L; Lubeck D; Chen MH
J Natl Cancer Inst; 2003 Sep; 95(18):1376-83. PubMed ID: 13130113
[TBL] [Abstract][Full Text] [Related]
11. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
12. [Prostate specific antigen doubling time in prostate cancer before treatment and in refractory status].
Nakata S; Takezawa Y; Kobayashi M; Kuribara H; Matumoto K; Kosaku N; Suzuki T; Yamanaka H
Nihon Rinsho; 1998 Aug; 56(8):2026-30. PubMed ID: 9750501
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of changes in prostate-specific antigen in patients with metastasis prostate cancer after endocrine treatment.
Furuya Y; Akakura K; Tobe T; Ichikawa T; Igarashi T; Ito H
Int Urol Nephrol; 2001; 32(4):659-63. PubMed ID: 11989560
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors for estrogen therapy of relapsed prostate cancer after maximal androgen blockade (MAB)].
Nakata S; Miyazawa Y; Sasaki Y; Nakano K; Takahashi H
Nihon Hinyokika Gakkai Zasshi; 2010 May; 101(4):597-602. PubMed ID: 20535987
[TBL] [Abstract][Full Text] [Related]
16. [PSA-doubling time immediately before the diagnosis of prostate cancer].
Nakata S; Hasumi M; Suzuki T; Sato J; Imai K; Yamanaka H; Shimizu T
Hinyokika Kiyo; 1998 Feb; 44(2):81-4. PubMed ID: 9546125
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of extension of disease as a prognostic factor in relapsed prostate cancer patients of stage D].
Kawai M; Uemura H; Hasumi H; Osada Y; Ohta J; Miyoshi Y; Mikata K; Oh-uchi H; Sugiura S; Fujinami K; Kubota Y
Nihon Hinyokika Gakkai Zasshi; 2005 Mar; 96(3):442-7. PubMed ID: 15828261
[TBL] [Abstract][Full Text] [Related]
18. Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men.
Kakehi Y; Kamoto T; Shiraishi T; Kato T; Tobisu K; Akakura K; Egawa S; Maeda O; Sumiyoshi Y; Arai Y; Ogawa O
Eur Urol; 2002 Jan; 41(1):47-53. PubMed ID: 11999465
[TBL] [Abstract][Full Text] [Related]
19. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
[TBL] [Abstract][Full Text] [Related]
20. [Utility of prostate specific antigen doubling time in repeat biopsy for prostate cancer].
Azuma K; Numata K; Hashine K; Sumiyoshi Y
Nihon Hinyokika Gakkai Zasshi; 2006 Jan; 97(1):42-7. PubMed ID: 16485553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
